Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin on CD34+ Endothelial Progenitor Cells in Type 2 Diabetes
NCT02964585Phase 4Completed
- Sponsor
- George Washington University
- Start
- Nov 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by George Washington University. Started Nov 2016; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02964585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964585.